← Leaderboards
Emmanuelle Joelle Meuillet
University Of Arizona
$3,671,425
Attributed
$4,332,839
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $747.8K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,332,839 · 6
By mechanism
R01$2,818,868 · 2
R33$925,231 · 1
R43$397,597 · 1
R03$145,583 · 1
F32$45,560 · 1
Top collaborators
- John J Pacella2 shared
- Henrik Carl Axel Odeen1 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Felicia D Goodrum$17,339,452
- Robert J Gillies$34,169,781
- Tony L Yaksh$23,138,803
- Janko Nikolich-Zugich$55,130,377
- David S Alberts$22,074,619
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelIn VitroBaseIn VivoMolecular TargetMalignant NeoplasmsTumorCellsMouse ModelIn Vivo ModelStructureOverexpressionMolecularTherapeutic TargetInhibitor/AntagonistExhibitsProductionCarcinogenesisComputer SimulationApplications GrantsBinding (Molecular Function)Cancer CellDesignProtein Isoforms
Grant awards (15)
Selectivity and Efficacy of CD90-targeted Phase Shift Microbubbles for HIFU-mediated Non-Thermal Ablation of Brain Tumors.$397,597
R43 · FY2022 · CA · contact PI
Ultrasound-mediated thrombolysis for MVO and PAO treatment.$350,219
R33 · FY2022 · HL · contact PI
Ultrasound-mediated thrombolysis for MVO and PAO treatment.$575,012
R33 · FY2021 · HL · contact PI
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac$294,653
R01 · FY2014 · CA · contact PI
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac$292,590
R01 · FY2013 · CA · contact PI
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac$333,334
R01 · FY2012 · CA · contact PI
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac$340,301
R01 · FY2011 · CA · contact PI
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac$355,842
R01 · FY2010 · CA · contact PI
Novel AKT PH domain inhibitors to prevent skin cancer$72,842
R03 · FY2010 · CA · contact PI
Novel AKT PH domain inhibitors to prevent skin cancer$72,741
R03 · FY2009 · CA · contact PI
Regulation of PTEN Activity in Cancer Cells$302,004
R01 · FY2005 · CA
Regulation of PTEN Activity in Cancer Cells$299,712
R01 · FY2004 · CA
Regulation of PTEN Activity in Cancer Cells$301,637
R01 · FY2003 · CA
Regulation of PTEN Activity in Cancer Cells$298,795
R01 · FY2002 · CA
Thioredoxin inhibits the tumor supressor, PTEN$45,560
F32 · FY2001 · CA